|Rapid Review Complete
|As monotherapy for the treatment of adult patients with relapsed or refractory classical Hodgkin lymphoma who have failed autologous stem cell transplant and brentuximab vedotin (BV), or who are transplant-ineligible and have failed BV.
|Rapid review commissioned
|Rapid review completed
|Rapid review outcome
|Full pharmacoeconomic assessment recommended at the submitted price.
The HSE has approved reimbursement following confidential price negotiations – November 2018.